FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 647 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas July 10, 2023 FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma August 14, 2025 Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis April 10, 2025 The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce September 27, 2018 Load more HOT NEWS First Mature Estimation of Median OS for Selpercatinib in Patients with... News on the Passing of the Lymphedema Treatment Act! Doctors Worry Breast Cancer Cases Are Being Missed as Mammogram Rates... OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and...
